Bharat Biotech releases the Covaxin Phase-3 trials
Hyderabad based Bharat Biotech has released the Phase-3 trial data for its India made Covid-19 vaccine – Covaxin to be 77.8% effective against the coronavirus. 
“130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%) participants with follow-up at least two weeks after the second vaccination; 24 occurred in the vaccine group and 106 in placebo recipients giving the vaccine overall efficacy of 77.8%.” the company said.
The vaccine has 93% efficacy against severe cases of Covid-19 and 63% efficacy against asymptomatic cases. The trial data released by the company has also suggested that the vaccine was effective against the Delta variant of the virus.
The side effects of the vaccine are reportedly not adverse, with participants of the trial not having any “clinically or statistically significant differences in the distributions of solicited, unsolicited, or serious adverse events” according to the company.
“BBV152 conferred 65.2% protection against the SARS CoV 2 Variant of Concern, B.1.617.2 (Delta),” the release by Bharat Biotech further stated.
